dc.date.accessioned | 2020-06-23T18:29:45Z | |
dc.date.available | 2020-06-23T18:29:45Z | |
dc.date.created | 2014-12-05T12:25:18Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Haabeth, Ole Audun Tveita, Anders Fauskanger, Marte Hotvedt Schjesvold, Fredrik Hellem Lorvik, Kristina Berg Hofgaard, Peter Olaf Omholt, Hilde Munthe, Ludvig Andre Dembic, Zlatko Corthay, Alexandre Bogen, Bjarne . How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?. Frontiers in Immunology. 2014, 5:174 | |
dc.identifier.uri | http://hdl.handle.net/10852/77154 | |
dc.description.abstract | CD4+ T cells contribute to tumor eradication, even in the absence of CD8+ T cells. Cytotoxic CD4+ T cells can directly kill MHC class II positive tumor cells. More surprisingly, CD4+ T cells can indirectly eliminate tumor cells that lack MHC class II expression. Here, we review the mechanisms of direct and indirect CD4+ T cell-mediated elimination of tumor cells. An emphasis is put on T cell receptor (TCR) transgenic models, where anti-tumor responses of naïve CD4+ T cells of defined specificity can be tracked. Some generalizations can tentatively be made. For both MHCIIPOS and MHCIINEG tumors, presentation of tumor-specific antigen by host antigen-presenting cells (APCs) appears to be required for CD4+ T cell priming. This has been extensively studied in a myeloma model (MOPC315), where host APCs in tumor-draining lymph nodes are primed with secreted tumor antigen. Upon antigen recognition, naïve CD4+ T cells differentiate into Th1 cells and migrate to the tumor. At the tumor site, the mechanisms for elimination of MHCIIPOS and MHCIINEG tumor cells differ. In a TCR-transgenic B16 melanoma model, MHCIIPOS melanoma cells are directly killed by cytotoxic CD4+ T cells in a perforin/granzyme B-dependent manner. By contrast, MHCIINEG myeloma cells are killed by IFN-γ stimulated M1-like macrophages. In summary, while the priming phase of CD4+ T cells appears similar for MHCIIPOS and MHCIINEG tumors, the killing mechanisms are different. Unresolved issues and directions for future research are addressed. | |
dc.language | EN | |
dc.publisher | Frontiers Media S.A. | |
dc.rights | Attribution 3.0 Unported | |
dc.rights.uri | https://creativecommons.org/licenses/by/3.0/ | |
dc.title | How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? | |
dc.type | Journal article | |
dc.creator.author | Haabeth, Ole Audun | |
dc.creator.author | Tveita, Anders | |
dc.creator.author | Fauskanger, Marte Hotvedt | |
dc.creator.author | Schjesvold, Fredrik Hellem | |
dc.creator.author | Lorvik, Kristina Berg | |
dc.creator.author | Hofgaard, Peter Olaf | |
dc.creator.author | Omholt, Hilde | |
dc.creator.author | Munthe, Ludvig Andre | |
dc.creator.author | Dembic, Zlatko | |
dc.creator.author | Corthay, Alexandre | |
dc.creator.author | Bogen, Bjarne | |
cristin.unitcode | 185,53,2,11 | |
cristin.unitname | Senter for immunregulering | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1181314 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Immunology&rft.volume=5:174&rft.spage=&rft.date=2014 | |
dc.identifier.jtitle | Frontiers in Immunology | |
dc.identifier.volume | 5 | |
dc.identifier.doi | https://doi.org/10.3389/fimmu.2014.00174 | |
dc.identifier.urn | URN:NBN:no-80258 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1664-3224 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/77154/1/Haabeth_et_al_2014_fimmu-05-00174.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 174 | |
dc.relation.project | NFR/214174;179573 | |